GR1008992B - Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης - Google Patents

Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης Download PDF

Info

Publication number: GR1008992B
Authority: GR; Greece
Prior art keywords: granules; metronidazole; pharmaceutical composition; coating; taste
Prior art date: 2015-12-17

Application number

GR20150100546A

Other languages

Greek (el)

English (en)

Inventor

Χρηστος Κωνσταντινου Κουτσοδημος

Γεωργιος Δημητριου Μοτσιος

Original Assignee

Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-17

Filing date

2015-12-17

Publication date

2017-03-23

2015-12-17 Application filed by Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων filed Critical Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων

2015-12-17 Priority to GR20150100546A priority Critical patent/GR1008992B/el

2016-12-16 Priority to PCT/GR2016/000068 priority patent/WO2017103631A1/fr

2017-03-23 Publication of GR1008992B publication Critical patent/GR1008992B/el

Links

239000008187 granular material Substances 0.000 title claims abstract description 85
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims abstract description 72
229960000282 metronidazole Drugs 0.000 title claims abstract description 62
239000006068 taste-masking agent Substances 0.000 title claims description 5
239000008203 oral pharmaceutical composition Substances 0.000 title abstract 2
239000011248 coating agent Substances 0.000 claims abstract description 46
238000000576 coating method Methods 0.000 claims abstract description 45
235000019640 taste Nutrition 0.000 claims abstract description 28
229920000642 polymer Polymers 0.000 claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 16
238000004519 manufacturing process Methods 0.000 claims abstract description 10
239000000203 mixture Substances 0.000 claims description 44
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 39
SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 20
229920001577 copolymer Polymers 0.000 claims description 18
239000003795 chemical substances by application Substances 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 15
JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 11
235000003599 food sweetener Nutrition 0.000 claims description 10
230000000873 masking effect Effects 0.000 claims description 10
239000003765 sweetening agent Substances 0.000 claims description 10
239000011230 binding agent Substances 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 9
238000001035 drying Methods 0.000 claims description 9
229960002476 metronidazole benzoate Drugs 0.000 claims description 8
CUUCCLJJOWSASK-UHFFFAOYSA-N metronidazole benzoate Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOC(=O)C1=CC=CC=C1 CUUCCLJJOWSASK-UHFFFAOYSA-N 0.000 claims description 8
239000000796 flavoring agent Substances 0.000 claims description 7
235000019634 flavors Nutrition 0.000 claims description 7
239000000843 powder Substances 0.000 claims description 7
239000007931 coated granule Substances 0.000 claims description 4
239000003995 emulsifying agent Substances 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 3
238000011282 treatment Methods 0.000 abstract description 20
208000015181 infectious disease Diseases 0.000 abstract description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
230000009747 swallowing Effects 0.000 abstract description 10
244000005700 microbiome Species 0.000 abstract description 6
239000007788 liquid Substances 0.000 abstract description 4
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
229920003134 Eudragit® polymer Polymers 0.000 description 28
239000004480 active ingredient Substances 0.000 description 24
239000003814 drug Substances 0.000 description 15
229940079593 drug Drugs 0.000 description 13
239000003826 tablet Substances 0.000 description 13
229940100692 oral suspension Drugs 0.000 description 12
239000012530 fluid Substances 0.000 description 11
229940063190 flagyl Drugs 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 8
239000011247 coating layer Substances 0.000 description 7
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
239000004148 curcumin Substances 0.000 description 6
235000019264 food flavour enhancer Nutrition 0.000 description 6
239000000463 material Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229940069328 povidone Drugs 0.000 description 6
239000007921 spray Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
239000000454 talc Substances 0.000 description 6
229910052623 talc Inorganic materials 0.000 description 6
235000012222 talc Nutrition 0.000 description 6
238000004090 dissolution Methods 0.000 description 5
239000010410 layer Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
208000004926 Bacterial Vaginosis Diseases 0.000 description 4
206010013911 Dysgeusia Diseases 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
208000025371 Taste disease Diseases 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
235000019333 sodium laurylsulphate Nutrition 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
229930006677 Erythromycin A Natural products 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
239000000783 alginic acid Substances 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229960001126 alginic acid Drugs 0.000 description 3
150000004781 alginic acids Chemical class 0.000 description 3
235000019658 bitter taste Nutrition 0.000 description 3
-1 conventional Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229960003276 erythromycin Drugs 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000003120 macrolide antibiotic agent Substances 0.000 description 3
235000019656 metallic taste Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
208000004881 Amebiasis Diseases 0.000 description 2
206010001980 Amoebiasis Diseases 0.000 description 2
241000606124 Bacteroides fragilis Species 0.000 description 2
239000004097 EU approved flavor enhancer Substances 0.000 description 2
241000207201 Gardnerella vaginalis Species 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000004376 Sucralose Substances 0.000 description 2
241000224527 Trichomonas vaginalis Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
239000008199 coating composition Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000007919 dispersible tablet Substances 0.000 description 2
235000020937 fasting conditions Nutrition 0.000 description 2
201000006592 giardiasis Diseases 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
235000012245 magnesium oxide Nutrition 0.000 description 2
239000000391 magnesium silicate Substances 0.000 description 2
235000019792 magnesium silicate Nutrition 0.000 description 2
229910052919 magnesium silicate Inorganic materials 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
239000007912 modified release tablet Substances 0.000 description 2
239000003607 modifier Substances 0.000 description 2
229940095353 oral granules Drugs 0.000 description 2
229960002085 oxycodone Drugs 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
239000008213 purified water Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
235000019408 sucralose Nutrition 0.000 description 2
BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
210000001779 taste bud Anatomy 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
235000019731 tricalcium phosphate Nutrition 0.000 description 2
241001148471 unidentified anaerobic bacterium Species 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
SKUIXNQQMIDEHM-UHFFFAOYSA-N 1-(2-methyl-4-nitro-1h-imidazol-5-yl)ethanol Chemical compound CC(O)C=1NC(C)=NC=1[N+]([O-])=O SKUIXNQQMIDEHM-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010005940 Bone and joint infections Diseases 0.000 description 1
208000014912 Central Nervous System Infections Diseases 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
208000037384 Clostridium Infections Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000001692 EU approved anti-caking agent Substances 0.000 description 1
229920003119 EUDRAGIT E PO Polymers 0.000 description 1
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010061977 Genital infection female Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
208000036209 Intraabdominal Infections Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
208000005448 Trichomonas Infections Diseases 0.000 description 1
206010044620 Trichomoniasis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000037009 Vaginitis bacterial Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
244000290333 Vanilla fragrans Species 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002744 anti-aggregatory effect Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000013736 caramel Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920003118 cationic copolymer Polymers 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
208000025222 central nervous system infectious disease Diseases 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000008029 eradication Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical compound O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000002346 layers by function Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000006191 orally-disintegrating tablet Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229940044476 poloxamer 407 Drugs 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

GR20150100546A 2015-12-17 2015-12-17 Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης GR1008992B (el)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GR20150100546A GR1008992B (el)	2015-12-17	2015-12-17	Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης
PCT/GR2016/000068 WO2017103631A1 (fr)	2015-12-17	2016-12-16	Composition pharmaceutique orale sous la forme de granules comprenant du métronidazole ou des dérivés de celui-ci et un agent de masquage du goût

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GR20150100546A GR1008992B (el)	2015-12-17	2015-12-17	Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης

Publications (1)

Publication Number	Publication Date
GR1008992B true GR1008992B (el)	2017-03-23

Family

ID=57851100

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR20150100546A GR1008992B (el)	2015-12-17	2015-12-17	Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης

Country Status (2)

Country	Link
GR (1)	GR1008992B (fr)
WO (1)	WO2017103631A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110773086B (zh) *	2019-11-20	2025-05-13	黄冈银河阿迪药业有限公司	模拟临界状态雾化流羟化合成甲硝唑的装置及其合成方法
CN113827572A (zh) *	2021-11-17	2021-12-24	华中药业股份有限公司	一种甲硝唑颗粒及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728403A (en) *	1994-10-05	1998-03-17	The Board Of Regents Of The University Of Nebraska	Coating technology for taste masking orally administered bitter drugs
US6221402B1 (en) *	1997-11-20	2001-04-24	Pfizer Inc.	Rapidly releasing and taste-masking pharmaceutical dosage form
US20050197434A9 (en) *	2002-08-27	2005-09-08	Hans-Ulrich Petereit	Granulate or powder for producing coating or binding agents for medicaments
US20090169620A1 (en) *	2007-12-21	2009-07-02	Venkatesh Gopi M	Orally disintegrating tablet compositions of temazepam

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4125048A1 (de) *	1991-07-29	1993-02-04	Peggy Albrecht	Arzneimittel mit verzoegerter freisetzung zur behandlung von periodontitis
FR2715067B1 (fr) *	1994-01-14	1996-04-05	Ethypharm Lab Prod Ethiques	Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal.
US6103262A (en)	1994-01-27	2000-08-15	G. D. Searle & Company	Modified-release metronidazole compositions and methods for making and using same
JP2001518490A (ja)	1997-10-03	2001-10-16	エランコーポレーシヨンピーエルシー	味遮蔽された製剤
FR2793690B1 (fr)	1999-03-30	2003-01-03	Cll Pharma	Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US6551617B1 (en)	2000-04-20	2003-04-22	Bristol-Myers Squibb Company	Taste masking coating composition
FR2821745B1 (fr)	2001-03-09	2004-07-02	Ethypharm Lab Prod Ethiques	Granules et granules enrobes au gout masque
CN1652750A (zh)	2002-04-03	2005-08-10	兰贝克赛实验室有限公司	红霉素a及其衍生物的味道掩蔽组合物
US20040258752A1 (en) *	2003-01-31	2004-12-23	Paruthi Manoj Kumar	Taste masking pharmaceutical composition and process for its preparation
CN1785162A (zh) *	2005-11-09	2006-06-14	济南百诺医药科技开发有限公司	根除幽门螺旋杆菌的双层片及其制备方法
NZ574544A (en)	2006-08-04	2011-12-22	Ethypharm Sa	Granule and orally disintegrating tablet comprising oxycodone

2015
- 2015-12-17 GR GR20150100546A patent/GR1008992B/el unknown
2016
- 2016-12-16 WO PCT/GR2016/000068 patent/WO2017103631A1/fr not_active Ceased

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728403A (en) *	1994-10-05	1998-03-17	The Board Of Regents Of The University Of Nebraska	Coating technology for taste masking orally administered bitter drugs
US6221402B1 (en) *	1997-11-20	2001-04-24	Pfizer Inc.	Rapidly releasing and taste-masking pharmaceutical dosage form
US20050197434A9 (en) *	2002-08-27	2005-09-08	Hans-Ulrich Petereit	Granulate or powder for producing coating or binding agents for medicaments
US20090169620A1 (en) *	2007-12-21	2009-07-02	Venkatesh Gopi M	Orally disintegrating tablet compositions of temazepam

Also Published As

Publication number	Publication date
WO2017103631A1 (fr)	2017-06-22

Publication	Publication Date	Title
US7294347B2 (en)	2007-11-13	Coating compositions for bitterness inhibition
EP1194153B1 (fr)	2004-05-06	Formulations pharmaceutiques liquides au gout masque.
US6767557B2 (en)	2004-07-27	Taste masked pharmaceutical compositions
EP1667660B1 (fr)	2014-11-12	Preparations multiparticulaires de pantoprazole
ZA200200344B (en)	2003-03-26	Method for making granules with masked taste and instant release of the active particle.
ES3061097T3 (en)	2026-03-31	Lacosamide pharmaceutical composition and pharmaceutical preparation thereof
US7153524B2 (en)	2006-12-26	Method for improving adsorption of a drug from ethylene oxide derivative
WO2009074995A1 (fr)	2009-06-18	Compositions à croquer de citrate de sildénafil au goût masqué
WO2004087111A1 (fr)	2004-10-14	Compositions pharmaceutiques orales a gout masque
GR1008992B (el)	2017-03-23	Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης
EP3331502B1 (fr)	2021-05-26	Formulations de propivérine à libération contrôlée
US20070167380A1 (en)	2007-07-19	Taste masked compositions of erythromycin a and derivatives thereof
US20240091217A1 (en)	2024-03-21	Stable pharmaceutical oral liquid formulation of an antispasmodic agent
JP2004520358A (ja)	2004-07-08	改良された治療効能を有するβ−ラクタム抗生物質を含む徐放性薬剤組成物
EP2808019B1 (fr)	2019-09-25	Composition de nitazoxanide améliorée et son procédé de préparation
WO2024184442A1 (fr)	2024-09-12	Composé et formulation pour thérapie systémique par administration transmuqueuse orale
US20130115300A1 (en)	2013-05-09	Ciprofloxacin dry syrup composition
WO2012080984A2 (fr)	2012-06-21	Comprimé pharmaceutique à libération contrôlée pour administration par voie orale
HK1086766B (en)	2016-03-11	Pantoprazole multiparticulate formulations
US20170071954A1 (en)	2017-03-16	Pediatric cholic acid formulation